Express Scripts expects earnings increase next year; India may exempt Sanofi's dengue vax from trials;

@FiercePharma: Shift in law helps local pharma groups in the Philippines. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: WuXi clarifies just what AstraZeneca is buying, or actually what it isn't buying. Report | Follow @EricPFierce

@CarlyHFierce: Valeant's rep-retention plan worked. Now, its sales folks are 'ready and waiting.' FiercePharmaMarketing story | Follow @CarlyHFierce

> Leading PBM Express Scripts ($ESRX) expects 2016 adjusted earnings of $6.08-$6.28 per share, an increase of 10% to 14% from the company's reaffirmed guidance for 2015. Report

> India's government may exempt Sanofi's ($SNY) dengue vaccine, Dengvaxia, from large-scale clinical trials. Report

> Genmab has achieved a $3 million milestone payment in its DuoBody collaboration with Johnson & Johnson's ($JNJ) Janssen. More

> Sobi has received an orphan drug designation for hemophilia med Alprolix in Switzerland. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: UCLA spinout nabs $10M Series A to diagnose, track traumatic brain injury. Report | Follow @FierceMedDev

@EmilyWFierce: Hey doc, what's on the menu when pharma comes calling? Hint: It's not health food. Story from FiercePharmaMarketing | Follow @EmilyWFierce

> Micro-cap liquid biopsy Dx player Biocept nabs $15M financing from Chicago growth investor. Report

> Olympus played down early report of superbug infections linked to duodenoscope devices. Article

Biotech News

@FierceBiotech: As trouble mounts, a chastened Martin Shkreli says bad boy persona was just an 'experiment.' Article | Follow @FierceBiotech

@JohnCFierce: Orbimed rings up $950M for biotech Fund VI. Report | Follow @JohnCFierce

@DamianFierce: this is a particularly belabored headline. FDA release | Follow @DamianFierce

> Pfizer, Merck KGaA launch two more PhIII trials for avelumab. Item

> Baxalta and Momenta target AbbVie's blockbuster with positive biosim data. Article

> With Big Pharma backing, eFFECTOR plots solid tumor trial with $40M round. Report

> pSivida shares soar as eye drug/device passes its first PhIII test. Story

Pharma Manufacturing News

> Sun said to be discussing $2.3B deal for Intas: DealStreetAsia. Item

> GSK recalls nearly 130,000 Ventolin inhalers. More

> Alnylam looks at building $100M plant outside Cambridge. Story

> Novartis selling French Alcon plant to Recipharm. Article

> Sun says the FDA has issued warning letter for Halol plant. Report

Drug Delivery News

> Antibiotic gel can prevent infection in bone implants. Report

> Eli Lilly partners with Halozyme to develop subcutaneous injectables. News

> FDA approves first chewable extended-release tablet, creating new drug delivery partnership opportunity. More

> J&J's Janssen teams up with Intrexon for diabetes pill. Story

> Startup gets $7M in funding to test its toenail fungus-fighting micro-insert. Article

Pharma Asia News

> Shift in law helps local pharma groups in the Philippines. Item

> Sun Pharma said to be in talks to buy Intas for $2.3B. Story

> 2015 was the year of the (most likely Chinese) health hacker: FT. More

> SciClone Pharmaceuticals sets mucositis treatment for China. Item

> Indian M&A deals top $1.5B in 2015 led by overseas acquisitions. Article

And Finally... The pharma industry will give £200 million to the U.K.'s NHS in early rebate payments to help it pay for meds. More

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.